Eyenovia, Inc. (EYEN) announced on Thursday a collaboration with SGN Nanopharma to create a new treatment for chronic dry eye disease. This partnership aims to combine SGN's Micellar Nanoparticle Platform-based cyclosporine formulation with Eyenovia's Optejet dispenser.
The collaboration involves both companies validating the manufacturability of this innovative drug-device combination product. Additionally, plans are underway to consult with the FDA to discuss the clinical development pathway.
Michael Rowe, CEO of Eyenovia, stated, "Previous studies have demonstrated that the Optejet dispenser can deliver a therapeutic dose with 80% less drug volume, which reduces exposure to harmful preservatives and enhances tolerability."
